Extension of Time to File SOU

BREYANZI

JUNO THERAPEUTICS, INC.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88569196
LAW OFFICE ASSIGNED LAW OFFICE 104
MARK SECTION
MARK http://uspto.report/TM/88569196/mark.png (stylized and/or with design)
STANDARD CHARACTERS NO
USPTO-GENERATED IMAGE NO
OWNER SECTION (current)
NAME JUNO THERAPEUTICS, INC.
INTERNAL ADDRESS 400 DEXTER AVENUENORTH
MAILING ADDRESS SUITE 1200
CITY SEATTLE
STATE Washington
ZIP/POSTAL CODE 98109
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
OWNER SECTION (proposed)
NAME JUNO THERAPEUTICS, INC.
INTERNAL ADDRESS 400 DEXTER AVENUENORTH
MAILING ADDRESS SUITE 1200
CITY SEATTLE
STATE Washington
ZIP/POSTAL CODE 98109
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME CAMILLE M. MILLER
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE cmiller@cozen.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME Camille M. Miller
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE cmiller@cozen.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) treginelli@cozen.com
DOCKET/REFERENCE NUMBER 453618/CELG-
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for the treatment of cancer and auto-immune diseases; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations for inhibiting cytokine production; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations, namely, preparations for use in the treatment of tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 12/17/2019
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /Camille M. Miller/
SIGNATORY'S NAME Camille M. Miller
SIGNATORY'S POSITION Attorney
DATE SIGNED 04/15/2020
SIGNATORY'S PHONE NUMBER 2156657273
FILING INFORMATION
SUBMIT DATE Wed Apr 15 08:27:49 ET 2020
TEAS STAMP USPTO/ESU-XX.XXX.XX.XXX-2
0200415082749561554-88569
196-7107c98dacbfe1d322088
e192705287652844bb29a2cb6
78cf4dadab8ae1f9e9996-CC-
27478443-2020041508253958
3390



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: BREYANZI (stylized and/or with design, see http://uspto.report/TM/88569196/mark.png)
SERIAL NUMBER: 88569196

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: JUNO THERAPEUTICS, INC., having an address of
      400 DEXTER AVENUENORTH
      SUITE 1200
      SEATTLE, Washington 98109
      United States
Proposed: JUNO THERAPEUTICS, INC., having an address of
      400 DEXTER AVENUENORTH
      SUITE 1200
      SEATTLE, Washington 98109
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/17/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of cancer and auto-immune diseases; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations for inhibiting cytokine production; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations, namely, preparations for use in the treatment of tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      CAMILLE M. MILLER
      PRIMARY EMAIL FOR CORRESPONDENCE: cmiller@cozen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Camille M. Miller
      PRIMARY EMAIL FOR CORRESPONDENCE: cmiller@cozen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): treginelli@cozen.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Camille M. Miller/      Date Signed: 04/15/2020
Signatory's Name: Camille M. Miller
Signatory's Position: Attorney
Signatory's Phone: 2156657273

RAM Sale Number: 88569196
RAM Accounting Date: 04/15/2020

Serial Number: 88569196
Internet Transmission Date: Wed Apr 15 08:27:49 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XXX-2020041508274956
1554-88569196-7107c98dacbfe1d322088e1927
05287652844bb29a2cb678cf4dadab8ae1f9e999
6-CC-27478443-20200415082539583390




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed